$797.3 M

PRAX Mkt cap, 10-Jun-2021
Praxis Precision Medicines Net income (Q1, 2021)-27.4 M
Praxis Precision Medicines EBIT (Q1, 2021)-27.4 M
Praxis Precision Medicines Cash, 31-Mar-2021131.2 M
Praxis Precision Medicines EV666.7 M

Praxis Precision Medicines Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

R&D expense

18.8m29.6m45.0m

General and administrative expense

3.9m6.2m17.0m

Operating expense total

22.7m35.8m62.0m

EBIT

(22.7m)(35.8m)(62.0m)

Interest expense

127.0k

Interest income

92.0k193.0k140.0k

Pre tax profit

(26.4m)(35.6m)(61.8m)

Income tax expense

133.0k(84.0k)(8.0k)

Net Income

(29.2m)(35.5m)(61.8m)

EPS

(22.5)(26.6)

Quarterly

USDQ1, 2021

R&D expense

17.9m

General and administrative expense

9.5m

Operating expense total

27.4m

EBIT

(27.4m)

Interest income

46.0k

Pre tax profit

(27.4m)

Net Income

(27.4m)

Praxis Precision Medicines Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

18.0m44.8m296.6m

Prepaid Expenses

5.7m

Current Assets

19.1m45.5m302.3m

PP&E

103.0k128.0k82.0k

Total Assets

19.8m47.7m303.2m

Accounts Payable

3.4m2.7m4.1m

Short-term debt

696.0k763.0k

Current Liabilities

3.4m6.8m15.7m

Long-term debt

763.0k763.0k

Total Debt

1.5m1.5m

Total Liabilities

5.1m7.6m15.7m

Common Stock

1.0k1.0k4.0k

Preferred Stock

55.7m121.1m

Additional Paid-in Capital

326.0k437.0m

Retained Earnings

(41.4m)(81.0m)(149.6m)

Total Equity

(41.0m)(81.0m)287.5m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

-0.5 x-0.6 x1.1 x

Quarterly

USDQ2, 2020Q1, 2021

Cash

19.7m131.2m

Prepaid Expenses

7.8m

Current Assets

20.4m278.6m

PP&E

108.0k109.0k

Total Assets

22.7m279.3m

Accounts Payable

3.7m5.8m

Short-term debt

729.0k578.0k

Current Liabilities

8.2m13.7m

Long-term debt

390.0k

Total Debt

1.1m578.0k

Total Liabilities

8.5m13.7m

Common Stock

1.0k4.0k

Preferred Stock

118.2m

Additional Paid-in Capital

442.5m

Retained Earnings

(104.1m)(176.9m)

Total Equity

(104.1m)265.5m

Financial Leverage

-0.2 x1.1 x

Praxis Precision Medicines Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(26.5m)(35.5m)(61.8m)

Depreciation and Amortization

1.0k37.0k50.0k

Accounts Payable

1.7m(837.0k)960.0k

Cash From Operating Activities

(20.7m)(33.4m)(52.6m)

Purchases of PP&E

(63.0k)(103.0k)

Cash From Investing Activities

(63.0k)(103.0k)

Cash From Financing Activities

37.8m60.4m304.4m

Net Change in Cash

17.0m26.9m251.8m

Quarterly

USDQ2, 2019Q2, 2020Q3, 2020Q1, 2021

Net Income

(17.5m)(19.9m)(36.1m)(27.4m)

Depreciation and Amortization

17.0k20.0k30.0k23.0k

Accounts Payable

553.0k912.0k544.0k2.2m

Cash From Operating Activities

(15.8m)(18.5m)(32.4m)(25.7m)

Purchases of PP&E

(74.0k)(4.0k)

Cash From Investing Activities

(74.0k)(140.0m)

Cash From Financing Activities

10.0m(6.6m)102.4m276.0k

Net Change in Cash

(5.8m)(25.1m)70.0m(165.5m)

Praxis Precision Medicines Ratios

USDFY, 2018

Financial Leverage

-0.5 x

Praxis Precision Medicines Operating Metrics

Q2, 2020

Discovery Stage Products

1

Pre-Clinical Phase Products

1

Phase I Trials Products

1

Phase II Trials Products

2